The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience

Table 1 Characteristics of patients

Characteristics	(n = 141)	Maximum CTC grade 1&2 infection	Maximum CTC grade 3&4 infection
Underlying disease
Indolent NHL	80	4	33
CLL	4	1	0
Aggressive NHL	49	6	32
ALL	4	0	3
AIHA	3	0	1
ITP	1	0	0
Therapeutic regimens used	(n = 141)
Rituximab monotherapy	23	1	3
R-CHOP	84	7	42
R-CHOEP	4	1	3
R-FC	6	2	4
R-FCM	2	0	0
R-DHAP	2	0	2
R-GMALL	7	0	5
R-Bendamustin	4	0	1
R-IMVP16	2	0	2
R-Gemcitabin	1	0	1
R-other	6	0	6
Comorbidities
Diabetes mellitus	18
Immunoglobulin deficiency	10
Asplenia	7
COPD	5
Chronic sinusitis	3

CTC: common toxicity criteria 4.0 of the National Institute of Health; NHL: non-Hodgkin lymphoma; CLL: chronic lymphocytic leukemia; ALL: acute lymphoblastic leukemia; AIHA: autoimmune hemolytic anemia; ITP: immunothrombocytopenic purpura, R-CHOP: Rituximab, cyclophosphamide, adriamycin, vincristine, prednisone; R-CHOEP: Rituximab, cyclophosphamide, adriamycin, vincristine, etoposide, prednisone; R-FC: Rituximab, fludarabine, cyclopsphamide; R-FCM: Rituximab, fludarabine, cyclopsphamide, mitoxantrone; R-DHAP: Rituximab, cytarabine, cisplatin, dexamethasone; R-GMALL: Rituximab in combination with the german GMALL induction; protocol for ALL-therapy; R-Bendamustin: rituximab and bendamustine; R-IMVP16: Rituximab, ifosfamide, etoposide, methotrexate; R-other: consisting of combination of other therapies such as R-DAHP + DB, R-CHOEP + R-BALL/BNHL, R-FCM + R-Bendamustin, R-FC + R-liposomal Doxorubicin, R-FCM + R-HAP, R-CHOP + R-FC + R-Bendamustine, COPD: chronic obstructive pulmonary disease.

ISSN: 1471-2334